DRUG

Bright Minds Biosciences Inc

Feb 19 • 04:00PM ET

86.08

+5.78 7.20 %

Healthcare • Biotechnology • USA • NASD

Peers: CMPS DFTX ATAI SAGE NBIX HELP RLMD GHRS CYPH

| Held by: IWM IWO VTWO VFMO IWC PSIL GWX VTWG RSSL IWV

Index	RUT	P/E	-	EPS (ttm)	-1.94	Insider Own	24.55%	Shs Outstand	7.79M	Perf Week	10.47%
Market Cap	842.72M	Forward P/E	-	EPS next Y	-7.27	Insider Trans	0.00%	Shs Float	7.38M	Perf Month	3.71%
Enterprise Value	777.84M	PEG	-	EPS next Q	-0.95	Inst Own	47.27%	Short Float	7.11%	Perf Quarter	48.41%
Income	-14.23M	P/S	-	EPS this Y	-249.96%	Inst Trans	11.06%	Short Ratio	2.88	Perf Half Y	101.92%
Sales	0.00M	P/B	10.29	EPS next Y	-59.54%	ROA	-26.63%	Short Interest	0.52M	Perf YTD	10.30%
Book/sh	8.36	P/C	12.97	EPS next 5Y	-	ROE	-27.03%	52W High	123.75 -30.44%	Perf Year	130.16%
Cash/sh	6.64	P/FCF	-	EPS past 3/5Y	35.51% -35.46%	ROIC	-21.85%	52W Low	23.17 271.43%	Perf 3Y	2291.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.40% 6.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-993.97%	Oper. Margin	-	ATR (14)	6.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	57.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.68	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	57.37	EPS Q/Q	-13290.57%	SMA20	7.24%	Beta	-5.95	Target Price	127.28
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.39%	Rel Volume	0.64	Prev Close	80.30
Employees	-	LT Debt/Eq	0.00	Earnings	Feb 15 AMC	SMA200	61.86%	Avg Volume	182.49K	Price	86.08
IPO	Mar 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	17.77% -	Trades		Volume	116,977	Change	7.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	BTIG Research	Buy	$72
May-13-25	Initiated	TD Cowen	Buy
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Jan-23-25	Initiated	Piper Sandler	Overweight	$93
Jan-10-25	Initiated	H.C. Wainwright	Buy	$85
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Initiated	Robert W. Baird	Outperform	$75

Feb-18-26 09:31PM	Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials (Insider Monkey) +7.20%
Feb-17-26 10:09AM	Canadian Securities Exchange Reports January 2026 Performance Figures (TMX Newsfile) +7.72%
Jan-09-26 11:56AM	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering (GlobeNewswire)
Jan-07-26 09:33PM	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock (GlobeNewswire) -6.22%
Jan-06-26 04:00PM	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering (GlobeNewswire) +16.50%
07:16AM	Loading…
07:16AM	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) (GlobeNewswire)
Jan-05-26 04:30PM	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 (GlobeNewswire)
Nov-26-25 08:55AM	Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why (Zacks)
Nov-25-25 04:30PM	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting (GlobeNewswire) +8.37%
09:55AM	Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet (Zacks)
Nov-17-25 05:29PM	Why Bright Minds Biosciences Stock Topped the Market on Monday (Motley Fool)
06:50AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) (GlobeNewswire)
Nov-06-25 06:30AM	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH (GlobeNewswire) +7.55%
Oct-30-25 06:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Oct-15-25 08:50AM	Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
09:55AM	Loading…
Sep-18-25 09:55AM	Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade (Zacks) +12.23%
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-04-25 08:30AM	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model (GlobeNewswire)
Sep-02-25 09:55AM	Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect? (Zacks)
03:50AM	Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy (Insider Monkey)
Aug-25-25 08:00AM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.14%
May-28-25 08:00AM	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 (GlobeNewswire)
May-13-25 08:30AM	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 (GlobeNewswire)
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
Apr-28-25 08:00AM	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study (GlobeNewswire)
Apr-16-25 12:09PM	Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (Seeking Alpha)
Mar-04-25 08:00AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research (GlobeNewswire) -7.70%
Feb-24-25 06:50AM	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March (GlobeNewswire)
06:50AM	Loading…
Jan-07-25 06:50AM	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DRUG

Bright Minds Biosciences Inc

Upgrade your FINVIZ experience